The Complainant H. Lundbeck A/S is an international pharmaceutical company engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, psychotic disorders, epilepsy and Huntington's, Alzheimer's and Parkinson's diseases.
Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 6,000 people worldwide.
Lundbeck is one of the world's leading pharmaceutical companies working with brain disorders. In 2011, the company's revenue was DKK 16.0 billion (approximately EUR 2.2 billion or USD 3.0 billion). For more information, reference is made to the official website www.lundbeck.com.
Lundbeck markets a number of different pharmaceuticals for the treatment of brain disorders. The most recently launched compounds include (using the Complainant's registered trademarks): Cipralex/Lexapro (depression), Ebixa (Alzheimer’s disease), Azilect (Parkinson’s disease), Xenazine (chorea associated with Huntington's disease), Sabril (epilepsy), Sycrest (bipolar disorder) and Onfi (Lennox-Gastaut syndrome).
The trademark Lexapro has been registered by the Complainant in more than 100 countries around the world.
The Respondent has registered and is using the contested domain name without the Complainant's consent for a website that contains pay-per-clock links and advertisements for businesses other than the Complainant, some of them in the pharmaceutical sector.
|